BTAIStock Financials & Fundamentals
Company Info
Company Full Name
BioXcel Therapeutics, Inc.
Full name of the company.
Industry Name
MEDICAL-BIOMED/GENETICS
Industry name
Major Industry Name
DRUGS
Major industry name
Sector Name
Medical
Sector name
Market Info
Current Price
$1.88
Current price of the stock
Trading Volume
$394K
Trading volume of the stock
Market Capitalization
$28.5M
Market capitalization of the company
Market Cap Category
Nano Cap
Category of market capitalization
Long-Term Growth Estimate
49.16%
Long-term growth mean estimate
Analyst Rating Mean
4.00
Mean analyst rating
Potential Upside
380.90%
Potential price appreciation based on analyst price targets
EPS Surprise Percentage Difference
-41.56%
Percentage difference of EPS surprise
Dividends
Dividend Change (1 Year)
-
Dividend change over 1 year
Dividend Rate
$0.00
Shows the amount of dividend paid
Balance Sheet
Total Debt to Equity Ratio
-1.23
Total debt to total equity ratio
Current Ratio
1.17
Current ratio
Company Profitability
Gross Profit Margin
88.78%
Gross profit margin
Operating Profit Margin
-14518.37%
Operating profit margin
EBIT Margin
-14518.37%
Earnings before interest and taxes (EBIT) margin
EBITDA Margin
-
Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin
Pretax Profit Margin
-31541.84%
Pretax profit margin
Net Profit Margin
-31541.84%
Net profit margin
Return on Equity (ROE)
34.76%
Measures profitability relative to shareholders' equity
Return on Tangible Equity
34.76%
ROE excluding intangible assets
Return on Assets (ROA)
-69.01%
Measures profitability relative to total assets
Return on Invested Capital (ROIC)
-913.71%
Measures profitability relative to invested capital
Management Effectiveness
Asset Turnover (quarterly)
0.00
Asset turnover ratio
Inventory Turnover (quarterly)
0.02
Inventory turnover ratio
Receivables Turnover (quarterly)
-
Receivables turnover ratio
Days Sales Outstanding
-
Average number of days it takes to collect receivables
Valuation Measures
Price-to-Earnings (P/E) Ratio
-0.28
Measures valuation relative to earnings
Forward P/E Ratio
-0.82
P/E based on future earnings estimates
Price-to-Sales (P/S) Ratio
37.94
Measures valuation relative to sales
Price-to-Book (P/B) Ratio
-0.45
Measures valuation relative to book value
Price-to-Operating Cash Flow (P/OCF) Ratio
-0.05
Measures valuation relative to operating cash flow
Price-to-Free Cash Flow (P/FCF) Ratio
-0.05
Measures valuation relative to free cash flow
Cash Flow Statement
Net Acquisitions/Divestitures
0
Indicates company's M&A activity
BTAIStock Financials & Fundamentals
Company Info
| Parameter | Value | Description |
|---|---|---|
| Company Full Name | BioXcel Therapeutics, Inc. | Full name of the company. |
| Industry Name | MEDICAL-BIOMED/GENETICS | Industry name |
| Major Industry Name | DRUGS | Major industry name |
| Sector Name | Medical | Sector name |
Market Info
| Parameter | Value | Description |
|---|---|---|
| Current Price | $1.88 | Current price of the stock |
| Trading Volume | $394K | Trading volume of the stock |
| Market Capitalization | $28.5M | Market capitalization of the company |
| Market Cap Category | Nano Cap | Category of market capitalization |
| Long-Term Growth Estimate | 49.16% | Long-term growth mean estimate |
| Analyst Rating Mean | 4.00 | Mean analyst rating |
| Potential Upside | 380.90% | Potential price appreciation based on analyst price targets |
| EPS Surprise Percentage Difference | -41.56% | Percentage difference of EPS surprise |
Dividends
| Parameter | Value | Description |
|---|---|---|
| Dividend Change (1 Year) | - | Dividend change over 1 year |
| Dividend Rate | $0.00 | Shows the amount of dividend paid |
Balance Sheet
| Parameter | Value | Description |
|---|---|---|
| Total Debt to Equity Ratio | -1.23 | Total debt to total equity ratio |
| Current Ratio | 1.17 | Current ratio |
Company Profitability
| Parameter | Value | Description |
|---|---|---|
| Gross Profit Margin | 88.78% | Gross profit margin |
| Operating Profit Margin | -14518.37% | Operating profit margin |
| EBIT Margin | -14518.37% | Earnings before interest and taxes (EBIT) margin |
| EBITDA Margin | - | Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin |
| Pretax Profit Margin | -31541.84% | Pretax profit margin |
| Net Profit Margin | -31541.84% | Net profit margin |
| Return on Equity (ROE) | 34.76% | Measures profitability relative to shareholders' equity |
| Return on Tangible Equity | 34.76% | ROE excluding intangible assets |
| Return on Assets (ROA) | -69.01% | Measures profitability relative to total assets |
| Return on Invested Capital (ROIC) | -913.71% | Measures profitability relative to invested capital |
Management Effectiveness
| Parameter | Value | Description |
|---|---|---|
| Asset Turnover (quarterly) | 0.00 | Asset turnover ratio |
| Inventory Turnover (quarterly) | 0.02 | Inventory turnover ratio |
| Receivables Turnover (quarterly) | - | Receivables turnover ratio |
| Days Sales Outstanding | - | Average number of days it takes to collect receivables |
Valuation Measures
| Parameter | Value | Description |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -0.28 | Measures valuation relative to earnings |
| Forward P/E Ratio | -0.82 | P/E based on future earnings estimates |
| Price-to-Sales (P/S) Ratio | 37.94 | Measures valuation relative to sales |
| Price-to-Book (P/B) Ratio | -0.45 | Measures valuation relative to book value |
| Price-to-Operating Cash Flow (P/OCF) Ratio | -0.05 | Measures valuation relative to operating cash flow |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.05 | Measures valuation relative to free cash flow |
Cash Flow Statement
| Parameter | Value | Description |
|---|---|---|
| Net Acquisitions/Divestitures | 0 | Indicates company's M&A activity |